臨床薬学講座 臨床薬剤学

• 講座概要
• 特徴的な臨床の取り組み
• 教授挨拶
• スタッフ
• 主な研究
• 主な業績

講座概要

臨床薬剤学分野では、臨床の場での薬剤師の実務を中心とした教育と研究を行い、医療の担い手となる薬剤師の育成を目指しています。医薬品は適正に使用されてこそ真価を発揮します。この医薬品の適正使用を支え、医療の質を確保することは薬剤師の大きな役割のひとつです。そのためのエビデンス創出にも力を注いでいます。

教授挨拶

医療の高度化と疾病構造の変化、そして超高齢社会は薬剤師の仕事にも大きな変化をもたらしています。チーム医療の進展と専門性を持った薬剤師の要請、地域社会や在宅医療の中での新たな役割など、薬剤師の臨床業務には一層の活躍が強く期待されています。本分野では、臨床のリアリティを学生と共有し、実践を重視した知識と技能の修得と同時に、医療人としての態度を追求します。また、優れた医療人となるためには基礎薬学・臨床薬学の研鑽と研究マインドは欠かすことができません。臨床の場には、まだまだわからないことが沢山あり課題解決を必要としています。患者さんのため、少しでも医療に貢献できるよう一緒に取り組みましょう。

講座スタッフ

教授	工藤　賢三	くどう　けんぞう
准教授	朝賀　純一	あさか　じゅんいち
講師	高橋　宏彰	たかはし　ひろあき

講座における主たる研究テーマ

• 抗がん剤の副作用発現回避および機構の解明
• 医療用麻薬貼付剤の経皮吸収性および疼痛コントロールの変動要因に関する研究
• 医薬品の適正使用に関する研究
• レギュラトリーサイエンスに関する研究

講座の主な業績

【令和７（2025）年度】

1. Nihei, S., Saito, K., Ikeda, T., Oikawa, T., Asahi, K., Asaka, J. and Kudo, K.: Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study. Cancer Chemotherapy and Pharmacology. 95(1): 55(2025)
2. Nihei, S., Ujiie, H., Saito, K., Ikeda, T., Asaka, J., Yaegashi, M., Asahi, K. and Kudo, K.: A prospective comparison of azilsartan and amlodipine for bevacizumab-induced hypertension and proteinuria in colorectal cancer. In Vivo. 40(1): 465-473(2026)
3. Saito, K., Nihei, S., Asaka, J. and Kudo, K.: Adverse reactions with VEGF inhibitors in combination with NSAIDs: disproportionality analysis using JADRE and FAERS. In Vivo. 39(3): 1458-1469(2025)
4. Saito, K., Nihei, S., Asaka, J. and Kudo, K.: Updating predictive model for cisplatin-induced acute kidney injury: incorporating concomitant medications and the standard supportive care. International Journal of Nephrology. Article ID: 6615898(2025)
5. Saito, K., Nihei, S., Asaka, J. and Kudo, K.: External validation and comparison of clinical prediction models for cisplatin-associated acute kidney injury: a single-centre retrospective study. Journal of Pharmaceutical Health Care and Sciences. 11(1): 82(2025)

【令和６（2024）年度】

1. Takahashi, H., Saito, Y., Sugawara, K., Sato, M., *Tairabune, T., Ujiie, H., Asaka, J. and Kudo, K.: Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study. Cancer Chemotherapy and Pharmacology. 93(4): 319-328(2024)
2. Omoto, T., Asaka, J. and Kudo, K.: Disproportionality analysis of osimertinib-related adverse events in elderly patients using the Japanese pharmacovigilance database. Cancer Diagnosis & Prognosis. 4: 631-637(2024)
3. Nihei, S., Asaka, J., Yaegashi, M., Asahi, K. and Kudo, K.: Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study. Journal of Pharmaceutical Health Care and Sciences. 10(1): 51(2024)
4. Ikeda, T., Nihei, S., Saito, K., Asaka, J. and Kudo, K.: Clinical characteristics of patients requiring emergency hospitalization due to immune-related adverse events: a retrospective study. Journal of Pharmaceutical Health Care and Sciences. 10(1): 78(2004)

【令和５（2023）年度】

1. Nihei, S., Ikeda, T., Aoki, T., Murasato, F., Yaegashi, M., Asahi, K., and Kudo, K.: Plasma endothelin1 may predict bevacizumabinduced proteinuria in patients with colorectal cancer. Cancer Chemother. Pharmacol., 91: 427-434 (2023)
2. Onodera, R., Chiba, S., Nihei, S., Fujimura, I., Akiyama, M., Utsumi, Y., Nagashima, H., Kudo, K. and *Maemondo, M.: High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study. J. Thorac. Dis., 15: 4237-4247 (2023)
3. *Kutsukake, M., *Kuwabara, N., *Miyate, Y., Kudo, K., *Goto, S., Taira, E. and Tachikawa, E.: Relationship between Ca2+ and cAMP as second messengers in ACTH-induced cortisol production in bovine adrenal fasciculata cells. Endocr. J., 70: 1123-1130 (2023)

【令和４（2022）年度】

1. Takahashi, H., Yaegashi, Y., Saito, Y., Nihei, S., *Tairabune, T., Ujiie, H., Asaka, J. and Kudo, K.: Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study. Journal of Pharmaceutical Health Care and Sciences, 8: 22 (2022)
2. *Chiba, T., Ujiie, H., Yaegashi, Y., *Umehara, K., *Takada, S., *Otaki, K., *Sako, K., *Nakamaru, Y., *Meada, T., Kudo, K., *Tasaki, Y. and *Sato, H.： Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab. Biomedical Reports, 17: 76 (2022)
3. Omoto, T., Asaka, J., Nihei, S. and Kudo, K.: Identifying risk factors for opioidinduced neurotoxicity in cancerpatients receiving oxycodone. Supportive Care in Cancer, 31: 208 (2023)
4. Nihei, S., Ikeda, T., Aoki, T., Murasato, F., Yaegashi, M., Asahi, K. and Kudo, K.: Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 91(5): 427-434 (2023)

【令和３（2021）年度】

1. Omoto, T., Asaka, J., *Sakai, T., Sato, F., *Goto, N. and Kudo, K.: Disproportionality analysis of safety signals for a wide variety of opioid-related adverse events in elderly patients using the Japanese Adverse Drug Event Report (JADER) database. Biological & Pharmaceutical Bulletin, 44(5): 627-634 (2021)
2. Ujiie, H., Nihei, S., Nishiya, N., Goto, S., Asakura, Y., Miura, S., Hirai, D., Endo, M., Oyake, T., Ito, S., *Chiba, T. and Kudo, K.: Switching from intravenous to oral tacrolimus reduces its blood concentration in paediatric cancer patients. Anticancer Research, 41(5): 2591-2596 (2021)
3. Takahashi, H., Asaka, J., *Tairabune, T., Ujiie, H., Matsuura, Y., Nihei, S., Kimura, T., *Chiba, T. and Kudo, K.: Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance. Journal of Clinical Pharmacy and Therapeutic, 46(5): 1404-1411 (2021)
4. Nihei, S., Asaka, J., Takahashi, H. and Kudo, K.: Bevacizumab increases endothelin-1 production via forkhead box protein O1 in human glomerular microvascular endothelial. International Journal of Nephrology. Article ID :8381115, (2021)
5. *Obara, R., *Tomita, T., *Goto, H., *Kohda, Y., *Yoshida, T. and Kudo, K.: Effect of antipsychotics on serum lithium levels and white blood cell counts. Neuropsychopharmacology Reports, 41(4): 532-537 (2021)
6. *Kobayashi, E., *Kanemaru, Y., *Shioya, K., Asaka, J., *Yuge, S., Kudo, K. and *Satoh, N.: A cross-sectional survey on COVID-19 knowledge and precautionary measures of the pharmacists and patients in community pharmacies. African Journal of Pharmacy and pharmacology, 16(1): 1-10 (2022)